Status:
RECRUITING
Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry
Lead Sponsor:
Changi General Hospital
Conditions:
Hypertension
Uncontrolled Hypertension
Eligibility:
All Genders
21-80 years
Phase:
NA
Brief Summary
* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This...
Detailed Description
• The investigators plan to achieve these aims in three steps. First, the investigators retrospectively assess medication adherence in 200 participants admitted for recent stroke using urine biospecim...
Eligibility Criteria
Inclusion
- Age of 21 - 80 years
- Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements
- Currently taking 2 or more hypertension medications
- Able to provide informed consent.
Exclusion
- Significant kidney impairment with eGFR of less than 45mL/min/1.73m2 or on dialysis
- Known history of chronic liver disease
Key Trial Info
Start Date :
February 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06938633
Start Date
February 7 2024
End Date
September 30 2025
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changi General Hospital
Singapore, Singapore